| Tyler Caphton Moffett, MD | |
|
1201 N Muldoon Rd, Anchorage, AK 99504-6104 | |
| (907) 257-4700 | |
| (907) 580-2090 |
| Full Name | Tyler Caphton Moffett |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 1201 N Muldoon Rd, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902817869 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Tyler Caphton Moffett, MD 37578 Captains Court Cir, Kenai, AK 99611-8794 Ph: (907) 395-0443 | Tyler Caphton Moffett, MD 1201 N Muldoon Rd, Anchorage, AK 99504-6104 Ph: (907) 257-4700 |
News Archive
ARIUS Research has announced that it has been granted two new United States patents for antibodies within their CD63 program. Patent 7,175,846. covers anti-cancer antibodies in ARIUS' partnered program for melanoma, breast and prostate cancers and protects the valuable site on the disease target that the drug candidate binds to.
A major UConn School of Medicine study published in the American Heart Association's flagship journal Circulation shows that more aggressively controlling daily blood pressure in older adults can improve brain health.
Bicycle-related head injuries fell significantly in the months after mandatory helmet legislation came into effect in NSW, and recent calls for a repeal of the laws should be rejected, new research based on hospital admissions data shows.
VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.
In their review paper recently published in the Indian Journal of Clinical Biochemistry, a group of authors discusses currently available and forthcoming CRISPR-based diagnostic assays, as well as the possibility of using the CRISPR/Cas system as a salient treatment or prevention strategy in the fight against coronavirus disease 2019 (COVID-19).
› Verified 3 days ago
Casey Mapes, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4300 B St Ste 200, Anchorage, AK 99503 Phone: 907-375-3355 Fax: 907-375-3351 | |
Stephen C Ellison, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4300 B St Ste 200, Anchorage, AK 99503 Phone: 907-375-3355 | |
Jonathan Daining, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 4300 B St, Suite 200, Anchorage, AK 99503 Phone: 907-375-3355 Fax: 907-375-3351 | |
Dr. Heath Wade Turner, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 4300 B St Ste 200, Anchorage, AK 99503 Phone: 907-375-3355 | |
Alisha Alexandra Skinner, M.D. Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 4300 B St Ste 200, Anchorage, AK 99503 Phone: 907-375-3355 Fax: 907-375-3355 | |
Esther Lee Hargrave, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4300 B St Ste 200, Anchorage, AK 99503 Phone: 907-375-3355 Fax: 907-375-3351 | |
Larry Scott Owen, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4300 B St, Suite 200, Anchorage, AK 99503 Phone: 907-375-3355 Fax: 907-375-3351 |